An eight-year-old Iranian boy who left his primary school in China for his mother country in January and later lost contact with his teachers for 42 days has returned to the campus, thrilling his classmates. On April 27, when the boy named Radin, dressed in the school’s uniform, appeared in a classroom at Shaoxing Boya International School, his excited classmates all came to hug him closely, the Y...
An eight-year-old Iranian boy who left his primary school in China for his mother country in January and later lost contact with his teachers for 42 days has returned to the campus, thrilling his classmates. On April 27, when the boy named Radin, dressed in the school’s uniform, appeared in a classroom at Shaoxing Boya International School, his excited classmates all came to hug him closely, the Yueniu News reported. “I asked my teacher not to tell them the news so this could be a surprise,”...
Police suspend ‘extensive’ six-day air and ground search in Nova Scotia, citing ‘no new information’ Teams in eastern Canada have called off an “extensive” six-day air and ground search of a rugged park for a missing Australian hiker . The Royal Canadian Mounted Police (RCMP) said this week it had suspended operations after an effort involving dogs, 100 people, aircraft and ground crews yielded “n...
Police suspend ‘extensive’ six-day air and ground search in Nova Scotia, citing ‘no new information’ Teams in eastern Canada have called off an “extensive” six-day air and ground search of a rugged park for a missing Australian hiker . The Royal Canadian Mounted Police (RCMP) said this week it had suspended operations after an effort involving dogs, 100 people, aircraft and ground crews yielded “no new information” in the whereabouts of Denise Ann Willams. Continue reading...
Global lenders to Sun Pharmaceutical Industries Ltd. are weighing multiple financing options for its proposed $12 billion acquisition of New York-listed healthcare company Organon & Co. , according to people familiar with the matter. The Indian drugmaker is considering seeking consent from Organon bondholders to swap their holdings into Sun Pharma debt, the people said, asking not to be identified...
Global lenders to Sun Pharmaceutical Industries Ltd. are weighing multiple financing options for its proposed $12 billion acquisition of New York-listed healthcare company Organon & Co. , according to people familiar with the matter. The Indian drugmaker is considering seeking consent from Organon bondholders to swap their holdings into Sun Pharma debt, the people said, asking not to be identified discussing private matters. It is also working on a potential euro-denominated bond that could carry a credit rating one to two notches higher than the one assigned to Organon before the proposed merger, they added. Separately, the company is planning to raise as much as $3 billion to $4 billion in offshore loans, the people said, adding that the deal is expected to get necessary approvals by December. The final funding could be a combination of all options, they said. The discussions highlight the scale of the deal, which would rank among the largest outbound acquisitions by an Indian drugmaker and aims to secure funding while preserving Sun Pharma’s credit profile. The latest funding proposal may replace an earlier bridge loan facility that Sun Pharma was seeking, the people said. At least three banks — Mitsubishi UFJ Financial Group Inc. , JPMorgan Chase & Co. and Citigroup Inc. — had committed to provide initial funding through a bridge facility, the people said. “Currently, three banks including Citi have underwritten the acquisition facility and will work with Sun extensively over next few months on multiple aspects and milestones of the acquisition including finalizing the long-term capital structure,” K Balasubramanian , CEO of Citi India and banking head of Indian subcontinent, said. Sun Pharma, JPMorgan and MUFG did not immediately reply to Bloomberg’s e-mailed queries seeking comments. In a presentation last month, Sun Pharma said it would use $2 billion to $2.5 billion from its cash reserves to help fund the acquisition.
US president says he is pausing US effort to guide stranded vessels out of the strait of Hormuz but blockade remains Donald Trump has announced that he is pausing ‘Project Freedom’, the US effort to guide stranded vessels out of the strait of Hormuz, so that he can finalise a deal with Iran, but added that his blockade of Iranian ports would remain in place. Trump announced the decision in a socia...
US president says he is pausing US effort to guide stranded vessels out of the strait of Hormuz but blockade remains Donald Trump has announced that he is pausing ‘Project Freedom’, the US effort to guide stranded vessels out of the strait of Hormuz, so that he can finalise a deal with Iran, but added that his blockade of Iranian ports would remain in place. Trump announced the decision in a social media post, saying he was pausing the effort for a short period to give space for US efforts to finalise a settlement with Iran to end the war. Continue reading...
(RTTNews) - Australian shares are trading notably higher on Wednesday, reversing the losses in the previous two sessions, with the benchmark S&P/ASX 200 moving well above the 8,700 level, following the broadly positive cues from Wall Street overnight, with gains in mining and fin
(RTTNews) - Australian shares are trading notably higher on Wednesday, reversing the losses in the previous two sessions, with the benchmark S&P/ASX 200 moving well above the 8,700 level, following the broadly positive cues from Wall Street overnight, with gains in mining and fin
Texas Doctor Found Guilty For Illegally Distributing Millions Of Opioid Pills Authored by Kimberly Hayek via The Epoch Times (emphasis ours), A federal jury in Texas found a physician guilty of unlawfully distributing over a million pills of opioids and other controlled substances from a Houston-area clinic that operated as a pill mill, the Justice Department announced Monday. Tablets of opioid pa...
Texas Doctor Found Guilty For Illegally Distributing Millions Of Opioid Pills Authored by Kimberly Hayek via The Epoch Times (emphasis ours), A federal jury in Texas found a physician guilty of unlawfully distributing over a million pills of opioids and other controlled substances from a Houston-area clinic that operated as a pill mill, the Justice Department announced Monday. Tablets of opioid painkiller Oxycodone delivered on medical prescription in Washington on Sept. 18, 2019. Eric Baradat/AFP via Getty Images Dr. Barbara Marino, 65, of Tomball, was the sole prescribing physician at Angels Clinica, where she prescribed oxycodone, hydrocodone, and the muscle relaxer carisoprodol despite no legitimate medical purpose. The clinic accepted only cash and charged based on the prescriptions. “Medical physicians who exploit their prescribing authority for profit over patient care break an inherent trust with their patients and we will hold them accountable,” Assistant Attorney General Colin M. McDonald of the Justice Department’s National Fraud Enforcement Division said in a statement. “The Department of Justice remains committed to protecting the public from dangerous and unlawful distribution of controlled substances, especially when the drug dealer is a doctor.” DEA Assistant Administrator Cheri Oz said patients put their trust and lives into the hands of medical and health care professionals. “The highly addictive, dangerous misused drugs in this case—oxycodone and hydrocodone—are meant to treat pain, not cause it,” Oz said. “DEA remains relentless in our pursuit of those who poison our communities and exploit our health care system, all to line their own pockets with the profit from other’s pain.” Prosecutors noted that many patients were delivered by street-level “crew leaders” or “runners” who then filled the prescriptions and peddled the pills. Marino received over $400,000 in less than a year for writing the scripts, while ignoring red flags outlined in Texas p...
CDC Data Centres is forecasting a surge in earnings over the next three years after agreeing Australia’s largest data center contract, stoking the value of its largest holder Infratil Ltd. The company expects operating earnings to rise to at least A$1 billion ($721 million) in the 2027-28 financial year from nearly A$400 million in the current year, it said on a conference call Wednesday in Wellin...
CDC Data Centres is forecasting a surge in earnings over the next three years after agreeing Australia’s largest data center contract, stoking the value of its largest holder Infratil Ltd. The company expects operating earnings to rise to at least A$1 billion ($721 million) in the 2027-28 financial year from nearly A$400 million in the current year, it said on a conference call Wednesday in Wellington. Shares in New Zealand infrastructure investor Infratil, which owns 49.7% of CDC, surged 12% in Wellington, the most in more than five years. CDC Chief Executive Greg Boorer said the contract win is a “massive tick of approval for Australia as a global hub for intelligence generation.” “It reaffirms Australia as a very trusted geography in a world that is getting increasingly geopolitically imbalanced,” he said. The contract, announced late Tuesday, is for 555 megawatts of new capacity and doubles CDC’s contracted capacity to 1 gigawatt. The deal is with an unidentified US customer and has a minimum term of 10 years. No financial details were provided with CDC saying it would be debt funded and requires no new equity from Infratil or other holders, which include Australia’s Future Fund and the Commonwealth Superannuation Corp. The capacity will be delivered over two years through 2029 on sites already under development. When fully deployed, the 1 gigawatt of contracted capacity would deliver annualized contracted operating earnings of about A$2 billion, the company said. CDC expects its capital spending in 2027-28 will be A$3.8 billion to A$4.2 billion, it said.
Earnings Call Insights: Logitech (LOGI) Q4 FY2026 Management View "Fiscal year '26 proved what our model is capable of in any environment, successful innovation, best-in-class execution and real earnings expansion," said CEO & Director Johanna Faber. "We captured significant new market share in key segments and geographies" and delivered "6% net sales growth in U.S. dollars and 4% in constant curr...
Earnings Call Insights: Logitech (LOGI) Q4 FY2026 Management View "Fiscal year '26 proved what our model is capable of in any environment, successful innovation, best-in-class execution and real earnings expansion," said CEO & Director Johanna Faber. "We captured significant new market share in key segments and geographies" and delivered "6% net sales growth in U.S. dollars and 4% in constant currency," alongside "non-GAAP gross margins of 43.6%" and "an operating margin of 18.8%." "In Q4, we again drove significant global market share growth with a 140 basis point increase in personal workspace," Faber said, adding: "We accelerated global gaming to high single-digit growth" and "delivered superb margins and a 25% increase in non-GAAP operating income versus last year." "With structurally strong gross margins and a pristine balance sheet, we'll invest in the business to accelerate future growth," Faber said, outlining three focus areas: "R&D and product innovation" (including "new Rally AI video conferencing cameras, which are shipping this summer"), "Logitech for Business" (prioritizing "education, government and health care"), and "building an iconic brand" using "proven high ROAS marketing." "The team delivered a very strong close to the year, characterized by solid demand, exceptional profitability and cash generation," said CFO Matteo Anversa. "Net sales were $1.086 billion" in Q4, and "our non-GAAP gross margin rate was exceptionally strong at 44.8%." Outlook "Net sales" in Q1 FY2027 are expected "to grow 2% to 4% in constant currency," Anversa said, and "this amount includes approximately 150 basis points of negative impact from the Middle East conflict." "Non-GAAP operating income is expected to be between $195 million and $215 million." "Making statements right now beyond the first quarter due to the visibility of -- in the current world conditions that we live in... it's a bit premature," Anversa said, while adding that OpEx would remain within "24% to 26%...
Earnings Call Insights: InnovAge Holding Corp. (INNV) Q3 fiscal 2026 Management view "We delivered a solid third quarter and continue to see steady momentum across the business." (Chief Executive Officer Patrick Blair) "For the quarter, we reported approximately $252 million in total revenue, center-level contribution margin of $61 million and adjusted EBITDA of $30 million." (CEO Blair) "Based on...
Earnings Call Insights: InnovAge Holding Corp. (INNV) Q3 fiscal 2026 Management view "We delivered a solid third quarter and continue to see steady momentum across the business." (Chief Executive Officer Patrick Blair) "For the quarter, we reported approximately $252 million in total revenue, center-level contribution margin of $61 million and adjusted EBITDA of $30 million." (CEO Blair) "Based on our year-to-date operating trends and financial performance, we are once again raising our fiscal year 2026 guidance for revenue and adjusted EBITDA." (CEO Blair) "We now expect revenue in the range of $950 million to $975 million and adjusted EBITDA in the range of $85 million to $90 million." (CEO Blair) "We ended the quarter serving approximately 8,050 participants in 6 states across 20 centers." (CEO Blair) "That includes continued investment in our clinical teams and interdisciplinary model, advancing our technology platform, including early and closely monitored applications of AI to improve care coordination and participant experience" and "strengthening how we measure and manage quality." (CEO Blair) "These may include acquisitions, joint ventures, partnerships or participation in new programs and demonstration models that align with our capabilities." (CEO Blair) "We expect Medicare rates to increase approximately 1.5% to 2% in fiscal year 2027" and "we are also being thoughtful about our assumptions as we look ahead to fiscal 2027." (CEO Blair) "Corporate general and administrative expenses of $76.5 million increased 98.3% compared to the third quarter of fiscal year 2025, primarily driven by an increase in litigation liability." (Chief Financial Officer Benjamin Adams) Outlook "We now expect revenue in the range of $950 million to $975 million and adjusted EBITDA in the range of $85 million to $90 million." (CEO Blair) "We expect our ending census for fiscal year 2026 to be between 7,900 and 8,100 participants and member months to be in the range of 92,900 to 95...